Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin

  • Authors:
    • Vasyl F. Chekhun
    • Natalia Yu. Lukyanova
    • Аnatoliy P. Burlaka
    • Natalia A. Bezdenezhnykh
    • Svitlana I. Shpyleva
    • Volodymyr P. Tryndyak
    • Frederick A. Beland
    • Igor P. Pogribny
  • View Affiliations

  • Published online on: August 20, 2013     https://doi.org/10.3892/ijo.2013.2063
  • Pages: 1481-1486
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The development of resistance of cancer cells to therapeutic agents is the major obstacle in the succesful treatment of breast cancer and the main cause of breast cancer recurrence. The results of several studies have demonstrated an important role of altered cellular iron metabolism in the progression of breast cancer and suggested that iron metabolism may be involved in the acquisition of a cancer cell drug-resistant phenotype. In the present study, we show that human MCF-7 breast cancer cells with an acquired resistance to the chemotherapeutic drugs doxorubicin (MCF-7/DOX) and cisplatin (MCF-7/CDDP) exhibited substantial alterations in the intracellular iron content and levels of iron-regulatory proteins involved in the cellular uptake, storage and export of iron, especially in profoundly increased levels of ferritin light chain (FTL) protein. The increased levels of FTL in breast cancer indicate that FTL may be used as a diagnostic and prognostic marker for breast cancer. Additionally, we demonstrate that targeted downregulation of FTL protein by the microRNA miR-133a increases sensitivity of MCF-7/DOX and MCF-7/CDDP cells to doxorubicin and cisplatin. These results suggest that correction of iron metabolism abnormalities may substantially improve the efficiency of breast cancer treatment.
View Figures
View References

Related Articles

Journal Cover

November 2013
Volume 43 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chekhun, V.F., Lukyanova, N.Y., Burlaka, А.P., Bezdenezhnykh, N.A., Shpyleva, S.I., Tryndyak, V.P. ... Pogribny, I.P. (2013). Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. International Journal of Oncology, 43, 1481-1486. https://doi.org/10.3892/ijo.2013.2063
MLA
Chekhun, V. F., Lukyanova, N. Y., Burlaka, А. P., Bezdenezhnykh, N. A., Shpyleva, S. I., Tryndyak, V. P., Beland, F. A., Pogribny, I. P."Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin". International Journal of Oncology 43.5 (2013): 1481-1486.
Chicago
Chekhun, V. F., Lukyanova, N. Y., Burlaka, А. P., Bezdenezhnykh, N. A., Shpyleva, S. I., Tryndyak, V. P., Beland, F. A., Pogribny, I. P."Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin". International Journal of Oncology 43, no. 5 (2013): 1481-1486. https://doi.org/10.3892/ijo.2013.2063